Waters Corporation WAT
433.54
3.24
0.75%
as of 25 Sep
- Market cap
- $42.3B
- P/E
- 108×
Follow WAT
Indexes
indicate stock being part of an index,
Insider Buys
alert about insiders buying in the last 12 month
Waters Corporation (WAT) P/S ratio
As of 25 September 2026, Waters Corporation (WAT) trades at a P/S ratio of 9.2×. Over the past ten years it has ranged from 4.6× (March 2020) to 9.8× (September 2021); the current reading is higher than 99% of that period. That is above the Diagnostics & Research industry median of 4.9× and above the Healthcare sector median of 3.8×.
P/S ratio, daily
Annual
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 7.1× | (4.02%) |
| FY2024 | 7.4× | 13.31% |
| FY2023 | 6.6× | (5.86%) |
| FY2022 | 7.0× | (15.30%) |
| FY2021 | 8.2× | 26.79% |
| FY2020 | 6.5× | (1.08%) |
| FY2019 | 6.6× | 9.39% |
| FY2018 | 6.0× | (11.24%) |
| FY2017 | 6.8× | 32.98% |
| FY2016 | 5.1× | (6.28%) |
Quarterly
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 7.9× | 22.23% |
| Mar 2026 | 6.5× | (9.15%) |
| Dec 2025 | 7.1× | 24.26% |
| Sep 2025 | 5.7× | (15.74%) |
| 42 more quarters | Free account |
Against its own ten years
Low 4.6×
High 9.8×
Ten-year median
6.4×
Current reading's percentile
99
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| DGX Quest Diagnostics Incorporated compare | 2.3× |
| IQV IQVIA Holdings Inc. compare | 2.6× |
| A Agilent Technologies, Inc. compare | 6.6× |
| MTD Mettler-Toledo International, Inc. compare | 7.4× |
| IDXX IDEXX Laboratories, Inc. compare | 9.0× |
| ILMN Illumina, Inc. compare | 9.2× |
| WAT Waters Corporation | 9.2× |
| GH Guardant Health, Inc. compare | 19.9× |
| NTRA Natera, Inc. compare | 21.8× |
| Diagnostics & Research industry median | 4.9× |
| Healthcare sector median | 3.8× |
| Market median | 2.0× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on WAT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement